期刊
NEURO-ONCOLOGY
卷 14, 期 11, 页码 1404-1412出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nos213
关键词
bevacizumab; CPT-11; efficacy; ependymoma; recurrent
资金
- Pediatric Brain Tumor Consortium [U01CA81457]
- National Center for Research Resources [M01RR00188]
- American Lebanese Syrian Associated Charities
A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in cases of pediatric recurrent ependymoma (EPN) to estimate sustained objective response rate and progression-free survival (PFS). Eligible patients received 2 doses of single-agent BVZ intravenously (10 mg/kg) 2 weeks apart and then BVZ CPT-11 every 2 weeks until progressive disease, unacceptable toxicity, or a maximum of 2 years of therapy. Correlative studies included diffusion-weighted and T1 dynamic contrast enhanced permeability imaging and tumor immunohistochemistry for vascular endothelial growth factor (VEGF)A and B, hypoxia inducible factor2, VEGF receptor (R)2, and carbonic anhydrase (CA)9. Thirteen evaluable patients received a median of 3 courses (range, 212) of BVZ CPT-11. No sustained response was observed in any patient. Median time to progression in 10 patients was 2.2 months (range, 1.96.3). Two patients had stable disease for 10 months and 12 months, respectively. Six-month PFS was 25.7 (SE 11.1). Grades IIII toxicities related to BVZ treatment included fatigue in 4 patients, systemic hypertension in 2, epistaxis in 1, headache in 1, and avascular necrosis of bone in 1. Although there was a decrease in the mean diffusion ratio following 2 doses of BVZ, it did not correlate with PFS. BVZ CPT-11 was well tolerated but had minimal efficacy in cases of recurrent EPN.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据